Policy Tracker

Federal status frames the baseline.

Ibogaine remains listed in Schedule I under the federal Controlled Substances Act. The DEA controlled-substances schedule identifies ibogaine within that federal framework; it does not by itself answer every question about research administration, state law, or a particular proposed measure.

Ongoing / federal
Research involving Schedule I substances may require DEA registration and FDA oversight where applicable. The FDA’s IND application procedures overview describes the pathway for investigational drug studies. A study authorization is not an approval for routine treatment, and it does not settle broader legal access.

For a wider introduction to the questions tracked here, the ibogaine research and safety overview sets the same distinction between preliminary developments and established evidence. The legal and practical consequences of a policy action can remain uncertain until agencies issue guidance, facilities meet applicable requirements, and the measure takes effect.

“Schedule status, research permission, and clinical authorization are different legal questions.”

State activity can be exploratory, not dispositive.

2024–2026 / selected state activity
State bills and task-force proposals concerning psychedelics have varied widely in scope. Some address research, advisory processes, data collection, or future regulatory design rather than ibogaine-specific authorization. Pending bills can be amended, delayed, or not enacted; enacted measures can still require rulemaking before any operational effect is clear.

A jurisdiction’s interest in study or review should not be read as a finding that ibogaine is safe, effective, or available. The National Conference of State Legislatures’ policy overview illustrates how state approaches can differ by substance, purpose, and legal mechanism.

Questions about function, recovery, and public interest can surface in different communities: the discussion of ibogaine and basketball, the context around ibogaine in soccer, and the material on ibogaine and hockey each benefit from separating public conversation from legal authorization.

• Date / when a bill is filed or enacted

  Primary change: identify whether the text creates a study, directs an agency, changes a criminal provision, or establishes a regulatory program. Outstanding question: does the text name ibogaine, and what later rules or federal constraints still apply?

• Date / when implementation materials appear

  Practical effect: look for an agency notice, appropriations, eligibility criteria, and an effective date. A legislative headline alone may not describe an available pathway.

Trial activity is not a verdict.

Current / approvals and registries
Clinical-trial listings and regulator actions can show that a protocol has been registered, reviewed, or authorized to proceed. They do not establish that an intervention works, is broadly safe, or is legally available outside research. The ClinicalTrials.gov study registry can help locate publicly listed studies, while the study record itself should be read for sponsor, status, inclusion criteria, and outcomes.

Safety questions require particular care because ibogaine has been associated with serious cardiac risk concerns in published and regulatory discussions. The safety and evidence materials keep that context close to questions of policy and access; neither a favorable proposal nor a research milestone removes the need for qualified medical and legal judgment.

Some public discussions center on aging or neurodegeneration, including material about ibogaine and brain aging, while others address specific conditions such as ibogaine and ALS. These conversations do not change the status of evidence or create a regulatory authorization.